European Pharmaceutical Review

JANUARY 26, 2024

A paper, published in Nature Chemical Biology has reported the first ‘free-from ‘tree’ production of a key vaccine ingredient sourced from the soapbark tree. Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree.

Vaccines 98

Vaccines Compounding Immunization 98

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Documentation Compounding FDA 108

European Pharmaceutical Review

MARCH 27, 2023

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 The research includes historic market data from 2017 to 2021, using 2022 as the base year. million in 2017 and continued to grow until 2021. percent between 2022 and 2027.

Compounding 115

Compounding Vaccines 115

pharmaphorum

AUGUST 31, 2022

The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% Though there are only three treatments approved, there are 1,986 gene therapies that are in various stages of development. from 2021 to 2029.

FDA 98

FDA Compounding Vaccines 98

ISPE

OCTOBER 26, 2022

ATMP facilities are different from conventional pharmaceutical facilities that process other traditional modalities, such as vaccines and monoclonal antibodies (mAbs), and often require heightened segregation and smaller footprints. Viral antigen vaccines. For example: Live vaccine manufacturing. Complete Data Gathering.

Vaccines 97

Vaccines Compounding Documentation FDA 97

European Pharmaceutical Review

JANUARY 29, 2024

Repurposing of currently marketed products, eg, methotrexate, 20 was an important and effective strategy in combatting COVID-19, particularly in the early stages prior to effective vaccines being developed. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [OBSOLETE].

FDA 111

FDA Vaccines Compounding 111

Hospital Pharmacy Europe

NOVEMBER 23, 2023

Similar findings were observed in previous iterations of the survey in 2016, 2017/18 and 2018/19. Few barriers were identified for hospital pharmacies to engage in the procurement, compounding and the distribution of medicines.

Hospitals 52

Hospitals Compounding Patient Care Vaccines 52